Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 7/20 | 0.49 |
| ▸ | ATP4B known ✓ | P51164 | 7/20 | 0.49 |
| ▸ | BRS3 | P32247 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.49 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.49 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.49 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.49 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.49 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.49 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.49 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.49 |
| ▸ | WDR5 | P61964 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL144577 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL28300201 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL665194 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL2484203 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1713666 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL6829013 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL4371701 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL142905 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29002845 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL28754295 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1066 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569475-B2 | Method for eradicating helicobacter pylori infection in patients regardless of body mass index | REDHILL BIOPHARMA LTD. (IL) | 2026-03-10 | — | — | US | claimed |
| CN-118948764-A | PH responsive chemical pharmaceutical composition for oral treatment of helicobacter pylori infection, preparation method and pharmaceutical preparation thereof | 华宇中研药业(北京)有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118090947-B | Quality detection technology and application of omeprazole magnesium compound chewable tablet | 青岛国信制药有限公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240325313-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI | REDHILL BIOPHARMA LTD. (IL) | 2024-10-03 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240100034-A1 | METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEX | REDHILL BIOPHARMA LTD. (IL) | 2024-03-28 | — | — | US | claimed |
| US-11931463-B2 | All-in-one fixed-dose combination for treating Helicobacter pylori infection | REDHILL BIOPHARMA LTD. (IL) | 2024-03-19 | — | — | US | claimed |
| CN-113384547-B | Omeprazole aluminum magnesium carbonate composite tablet and preparation process thereof | 上海信谊万象药业股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117398360-B | Compound preparation capsule for treating helicobacter pylori and preparation method thereof | 山东齐都药业有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-11878011-B2 | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index | REDHILL BIOPHARMA LTD. (IL) | 2024-01-23 | — | — | US | claimed |
| CN-1126993-A | Omeprazole Magnesium | ASTRA AB (SE) | 1996-07-17 | — | — | CN | claimed |
| CN-1126946-A | New pharmaceutical formulation | ASTRA AB (SE) | 1996-07-17 | — | — | CN | claimed |
| EP-0707580-A1 | MAGNESIUM OMEPRAZOLE | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | claimed |
| EP-0706378-A1 | NEW PHARMACEUTICAL FORMULATION | Astra Aktiebolag (SE) | 1996-04-17 | — | — | EP | claimed |
| WO-1995001977-A9 | MAGNESIUM OMEPRAZOLE | — | 1996-02-01 | — | — | WO | claimed |
| WO-1996001622-A1 | NEW ORAL PHARMACEUTICAL FORMULATION CONTAINING MAGNESIUM SALT OF OMEPRAZOLE | ASTRA AKTIEBOLAG (SE) | 1996-01-25 | — | — | WO | claimed |
| EP-0652872-A1 | OPTICALLY PURE SALTS OF PYRIDINYLMETHYL SULFINYL-1H-BENZIMIDAZOLE COMPOUNDS | Astra Aktiebolag (SE) | 1995-05-17 | — | — | EP | claimed |
| WO-1995001783-A1 | NEW PHARMACEUTICAL FORMULATION | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | claimed |
| WO-1995001977-A1 | MAGNESIUM OMEPRAZOLE | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | claimed |
| WO-1994027988-A1 | OPTICALLY PURE SALTS OF PYRIDINYLMETHYL SULFINYL-IH-BENZIMIDAZOLE COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569475-B2 | Method for eradicating helicobacter pylori infection in patients regardless of body mass index | FABP6, RPS6, MRPL21 | ATP4A 844/4885ATP4B 683/4885BRS3 1827/4885 |
| US-20240100034-A1 | METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEX | FABP6, ALPI, RPL32 | ATP4A 643/4885ATP4B 649/4885BRS3 2337/4885 |
| US-11878011-B2 | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index | FABP6, ALPI, RPL32 | ATP4A 643/4885ATP4B 649/4885BRS3 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.